The study of Dipeptidyl peptidase-IV inhibitor's efficacy and safety when it is applied on type 2 diabetes whose blood suger was poorly controlled with original oral antidiabetic drug

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003858

Enrollment

Unknown

Registered

2013-10-10

Start date

2013-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

2 groups: saxagliptin vs Vildagliptin

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Signed informed consent; 2. Aged 18 to 70 years type 2 diabetic patients, the original therapy in stable for more than 2 months, poor blood sugar control; 3. visit 1, body mass index (BMI) in 18.5-40 kg/m2 (including 18.5-40 kg/m2).

Exclusion criteria

Exclusion criteria: 1. In patients with type 1.1 diabetes, or secondary diabetes mellitus; 2. pregnancy or breast-feeding women (Mi Ru); 3. diabetic emergencies such as: acute infection, stress, peri operation period, the use of corticosteroids, acute heart, brain, kidney failure state; 4. diabetic ketoacidosis or hyperosmolar nonketotic coma history; 5. The researchers think that patients can not be any situation successfully completed research; 6. plus other antidiabetic drugs, serious adverse drug reaction, are unwilling to continue the medication and the respondent.

Design outcomes

Primary

Measure	Time frame
glycosylated hemoglobin;	—

Countries

China

Contacts

Public ContactTan YuYu

The First Hospital, Guangzhou Medical University

yy_tan@163.com+86 020-83062305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 2, 2026